MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

166 / 349 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2026, 17:11 UTC

Suurimad hinnamuutused turgudel

Uudisväärsed sündmused

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2. apr 2026, 17:10 UTC

Uudisväärsed sündmused

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3. apr 2026, 00:00 UTC

Uudisväärsed sündmused

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2. apr 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Capital Finalize China JV

2. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. apr 2026, 20:41 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2. apr 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2. apr 2026, 20:01 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2. apr 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2. apr 2026, 19:29 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:24 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2. apr 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2. apr 2026, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2. apr 2026, 19:00 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Agreement Reached With American Train Dispatchers Association

2. apr 2026, 18:24 UTC

Omandamised, ülevõtmised, äriostud

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2. apr 2026, 17:44 UTC

Market Talk

Uudisväärsed sündmused

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2. apr 2026, 17:32 UTC

Uudisväärsed sündmused

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2. apr 2026, 17:26 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2. apr 2026, 17:09 UTC

Market Talk

Uudisväärsed sündmused

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

166 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.